Egfr Overexpression Effect
Egfr Overexpression Effect - Related Videos
05:16
Detecting Histone Modifications in Yeast Cells with Neurodegenerative Protein Overexpression
0 Views •
2025
Source: Bennett, S. A., et al., Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models. J. Vis. Exp. (2019).This video demonstrates the procedure of assessing histone modifications in yeast cells overexpressing neurodegenerative proteins. The steps include cell lysis, centrifugation, electrophoresis, membrane transfer, and antibody-based detection of modified histones.
08:13
Overexpressing and Purifying a Toxic Nuclease from Escherichia coli
0 Views •
2025
This article describes a methodology for overexpressing recombinant Nsp15, a toxic nuclease, in a C41(DE3) expression system, followed by purification of the tagged protein utilizing affinity and size exclusion chromatography. These protocols can be adapted for other challenging toxic proteins.
08:12
Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes
0 Views •
Cited by 5 •
2011
We describe how to perform retroviral or lentiviral infections of overexpression or shRNA-containing constructs in the human Ramos B-cell line and how to measure somatic hypermutation in these cells.
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
FAQs
More receptor molecules at the cell surface increase the opportunity for ligand-driven receptor pairing, or dimerization. This pairing enables autophosphorylation, in which receptor proteins add phosphate groups to themselves and create signaling sites. As a result, a ligand stimulus can generate stronger or more sustained intracellular signals than it would under normal receptor abundance.
Two major downstream routes are the RAS-RAF-MEK-ERK pathway and the PI3K-AKT pathway. Their activation connects receptor phosphorylation with changes in cell behavior: the first is associated with growth and division signals, while the second supports survival-related signaling. Examining both routes helps explain why increased EGFR activity can influence several cellular outcomes at once.
Heightened EGFR signaling can promote cell proliferation, survival, and migration while reducing responsiveness to normal growth controls. These effects do not represent separate receptor functions; they arise from amplified downstream signaling that changes how cells respond to growth-related cues. In tumor cells, this combination can support continued expansion and more aggressive cellular behavior.
EGFR overexpression provides a biological explanation for how abnormal receptor activity can contribute to cancer development. By amplifying signals that favor proliferation and survival, it may help tumor cells maintain growth despite normal regulatory constraints. Studying this relationship connects molecular signaling changes with broader patterns of tumor behavior and helps identify mechanisms that may influence disease progression.
The amount of EGFR and the activity of its downstream signaling pathways can provide information about the molecular state of tumor cells. Such information may help identify biomarkers, which are measurable biological features used to characterize disease or anticipate treatment behavior. Comparing EGFR-related patterns with cellular responses can therefore support more informed interpretation of tumor biology and therapy outcomes.
Tumors with amplified EGFR signaling may respond differently to therapies because their growth and survival depend more strongly on receptor-linked pathways. This variation makes EGFR status relevant when interpreting treatment outcomes. Targeted approaches can inhibit EGFR itself or interfere with downstream signaling pathways, helping researchers examine whether reducing this activity changes tumor-cell behavior or therapeutic response.